Gilead Sciences | GILD - Trade Debtors


Gilead Sciences reported $4.74B in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
ALKERMES USD 407.63M 73.6M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amgen USD 9.14B 432M Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Glaxosmithkline GBP 10.45B 707.81M Dec/2025
Incyte USD 1.05B 27.09M Mar/2026
J&J USD 21.33B 3.72B Dec/2025
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026